Lamotrigine vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Lamotrigine
Marketed by GlaxoSmithKline
NCT01431976 · Phase 3 · completed
This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.
Reported efficacy
Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 (missed)
Result source: NCT00088452
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.
The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.
Reported efficacy
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)
Result source: NCT00334958
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lamotrigine | Rufinamide |
|---|---|---|
| Seizure frequency, % change | 75.4% vs 32.1%+43.3 vs placeboNCT00104416 | —Not reported |
| 50% responder rate | —Not posted · NCT00007670 | —Not reported |
| Seizure freedom | —Not posted · NCT00007670 | —Not reported |
Seizure frequency, % change
- Lamotrigine
- 75.4% vs 32.1%+43.3 vs placeboNCT00104416
- Rufinamide
- —Not reported
50% responder rate
- Lamotrigine
- —Not posted · NCT00007670
- Rufinamide
- —Not reported
Seizure freedom
- Lamotrigine
- —Not posted · NCT00007670
- Rufinamide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lamotrigine: 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lamotrigine | Rufinamide |
|---|---|---|
| Dropout rate | 70%a NCT01431976 · Phase 3 · monotherapy show 16 more results0% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 52.2% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 20% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 16.8%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 30.1%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 13.2% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 21%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 24.1% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 30%a NCT01431976 · Phase 3 · monotherapy show 16 more results— NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 26.9% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 8.8%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.3% NCT00104416 · Phase 3 · registry result, not featured evidence — NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 15.3%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 12% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 7.4% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01431976 · Phase 3 · monotherapy show 16 more results1.3% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 0% NCT02404168 · Phase 4 · registry result, not featured evidence 0% NCT01995825 · Phase 4 · registry result, not featured evidence 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence 3.3% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 9.8%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 4.5%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.4% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence 0% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | 3.4%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results3.4% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 16.7% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 13 more resultsfatigue 8.7% headache 8.1% hostility 6.7% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 headache 11.4% dizziness 5.7% blurred vision 2.9% NCT01995825 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.1% headache 21.5% rash 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence dizziness 25.6% balance disorder 20.7% fall 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence diplopia 10% dizziness 6.7% insomnia 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence upper respiratory tract inflammation 29.4% nasopharyngitis 27.5% diarrhoea 21.6% NCT00395694 · Phase 3 · registry result, not featured evidence dizziness 19.6% nasopharyngitis 19.6% contusion 15.7% NCT00395694 · Phase 3 · registry result, not featured evidence 300 mg headache 17.9% dizziness 6% nausea 3.3% NCT00355082 · Phase 3 · registry result, not featured evidence 300 mg headache 25.9% dizziness 10.7% nasalpharyngitis 6.3% NCT00355082 · Phase 3 · registry result, not featured evidence 250 mg headache 27.9% rash 10.8% dizziness 9% NCT00355082 · Phase 3 · registry result, not featured evidence headache 13.9% (placebo 16.2%) vomiting 9.7% (placebo 4.1%) nausea 6.9% (placebo 5.4%) NCT00104416 · Phase 3 · registry result, not featured evidence somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy | b dizziness 26.7% (placebo 8.3%) headache 16.5% (placebo 12.8%) fatigue 15.3% (placebo 10%) NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more resultsnasopharyngitis 31% (placebo 30%) status epilepticus 27.6% (placebo 16.7%) decreased appetite 20.7% (placebo 6.7%) NCT01146951 · Phase 3 · monotherapy upper respiratory tract infection 28% vomiting 28% somnolence 20% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 nasopharyngitis 48.1% status epilepticus 40.7% somnolence 25.9% NCT01151540 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 16 of these studies.
- bPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lamotrigine
show 2 more results
show 2 more results
show 13 more results
show 1 more result
+ 15 further endpoints in the CSV export.
Rufinamide
+ 5 further endpoints in the CSV export.
Lennox-Gastaut Syndrome
Shared mechanism: Voltage-gated sodium channel · full Lennox-Gastaut Syndrome pipeline
Lamotrigine
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Rufinamide
Marketed by Eisai and partners
NCT01146951 · Phase 3 · completed
Participants were randomized to quadruple-blind rufinamide or placebo, with 59 entering treatment and 58 included in the full analysis set. The primary clinical endpoint was met, with a statistically significant reduction in tonic-atonic seizure frequency, but the small sample limits the strength of the evidence.
Reported efficacy
Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)): Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) (Baseline (28 day observational period) and End of Treatment (28 day treatment period)): Rufinamide (E2080) -24.2 Percent Change (range -93.5 to 27.2) | Placebo -3.25 Percent Change (range -81.6 to 151.9) (met)
Result source: NCT01146951
Results for Lennox-Gastaut Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Lamotrigine: no structured comparison results are available for Lennox-Gastaut Syndrome.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rufinamide
+ 4 further endpoints in the CSV export.
Available safety results
Rufinamide
| Dropout rate | 13.8% NCT01146951 · Phase 3 · monotherapy show 2 more results40% NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 24.1% NCT01151540 · Phase 3 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 13.8% NCT01146951 · Phase 3 · monotherapy show 2 more results12% NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 7.4% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3.4% NCT01146951 · Phase 3 · monotherapy show 2 more results40% NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 16.7% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | nasopharyngitis 31% (placebo 30%) status epilepticus 27.6% (placebo 16.7%) decreased appetite 20.7% (placebo 6.7%) NCT01146951 · Phase 3 · monotherapy show 2 more resultsupper respiratory tract infection 28% vomiting 28% somnolence 20% NCT01405053 · Phase 3 · registry result, not featured evidence · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 nasopharyngitis 48.1% status epilepticus 40.7% somnolence 25.9% NCT01151540 · Phase 3 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lamotrigine's landscape · Rufinamide's landscape